Metzger Michael A, serving as Director and Officer, purchased 157,307 shares of SNDX at a price of $10.90, amounting to a total trade value of $1,714,646.30. This transaction is likely a bullish signal given the substantial investment and the current share price of $16.37, which reflects significant appreciation.
Company: Syndax Pharmaceuticals (SNDX)
Role: Director, Officer
Metzger Michael A has demonstrated a strong trading performance with recent trades showing significant positive outcomes. A notable trade was made at a purchase price of $10.9, with the current price at $16.37, reflecting a lucrative gain.
There is no significant cluster activity observed recently. However, neither the CEO nor the CFO have engaged in recent trades.
Average Return: 16.76%
Average Holding Time: 114 days
Consistent Profitability: The trades were generally profitable with significant returns noted at 30 and 60 days.
Trade Size Comparison: The current trade size is substantial compared to past trades by the same insider.
The insider's past trades have been mostly profitable, particularly in the short to mid-term periods, though there was a notable decline over the 1-year mark. The current trade size is significant, suggesting a strong signal of confidence. This pattern may suggest optimism for short to mid-term appreciation.
The insider trade by Metzger Michael A, who is a Director and Officer, shows a significant purchase size executed in the open market. This indicates a strong personal financial commitment, suggesting confidence in the company's future performance. However, the absence of cluster activity limits the strength of this signal.
Overall, while the trade suggests a personal vote of confidence in the company's prospects, the lack of additional insider activity tempers the conviction to medium.
The insider trade by Metzger Michael A., involving the purchase of 157,307 shares at $10.9, is interpreted as bullish given its alignment with a 30-day return of 31.17% and a 60-day return of 66.7%. Historically, Metzger's trades have shown a strong win rate, suggesting a keen insight into timing and market conditions. This transaction size appears significant but not an outlier for Metzger, indicating confidence without excessive risk. With the current price at $16.37 and timing aligned near recent recovery highs, this move likely precedes a material upward trend, capitalizing on recent momentum and mitigating prior year losses of -14.29%.
Director and Officer Metzger Michael A's purchase of 157,307 shares at $10.90 is a bullish signal that often precedes momentum, and it's worth watching for both short-term and mid-term entries given the 31.17% 30-day return.